Also found in: Dictionary.



Pharmacologic class: Monoclonal antibody

Therapeutic class: Immunologic agent

Pregnancy risk category C

FDA Box Warning

• Drug may cause GI perforation, in some cases leading to death. Include such perforation in differential diagnosis of patients who experience abdominal pain during therapy. Discontinue permanently in patients with GI perforation.

• Drug may lead to potentially fatal wound dehiscence. Discontinue permanently in patients with wound dehiscence requiring medical intervention.

• Serious and, in some cases fatal, hemoptysis has occurred in patients with non-small-cell lung cancer who received chemotherapy and bevacizumab. Don't give to patients with recent hemoptysis.


Binds to vascular endothelial growth factor, preventing or reducing micro-vascular formation and growth and inhibiting metastatic disease progression


Solution for injection: 25 mg/ml in 4-ml and 16-ml vials

Indications and dosages

First-line treatment of metastatic cancer of colon or rectum (used in combination with 5-fluorouracil [5-FU]-based chemotherapy)

Adults: 5 mg/kg I.V. infusion q 14 days until disease progression occurs when used with 5-FU, irinotecan, and leucovorin or 10 mg/kg I.V. infusion q 14 days until disease progression occurs when used with 5-FU, oxaliplatin, and leucovorin

Unresectable, locally advanced, recurrent or metastatic nonsquamous, non-small-cell lung cancer

Adults: 15 mg/kg I.V. infusion q 3 weeks




Use cautiously in:

• hypersensitivity to drug

• cardiovascular disease

• development of immunogenicity

• patients sensitive to infusion reactions

• patients recovering from major surgery, nongastrointestinal fistula

• recent history of hemoptysis (Don't administer drug.)

• patients with proteinuria

• elderly patients

• pregnant or breastfeeding patients

• children.


• Withdraw necessary amount to obtain required dose, and dilute in 100 ml of 0.9% sodium chloride injection.

Don't mix or administer drug with dextrose solutions.

Don't deliver by I.V. push or bolus.

• Initially, infuse drug over 90 minutes. If patient tolerates infusion well, infuse over 60 minutes the second time; if he continues to tolerate it well, infuse each dose over 30 minutes thereafter.

Withhold dose if hypertension occurs.

Stop infusion if patient develops infusion reaction, hypertensive crisis, severe bleeding, abdominal pain (may signal intra-abdominal abscess or GI perforation), wound dehiscence, or urinary problems.

• Be aware that drug shouldn't be given within 28 days after major surgery and that therapy should be suspended several weeks before elective surgery.

Adverse reactions

CNS: asthenia, dizziness, headache, confusion, syncope, abnormal gait, transient ischemia attack, reversible leukoencephalopathy syndrome, cerebral infarction

CV: hypotension, hypertension, angina, hypertensive crisis, heart failure, deep-vein thrombosis, intraabdominal thrombosis, thromboembolism, MI

EENT: excess lacrimation, visual disturbances, rhinitis, severe epistaxis

GI: nausea, vomiting, diarrhea, constipation, abdominal pain, stomatitis, dyspepsia, flatulence, colitis, dry mouth, anorexia, GI perforation, intra-abdominal abscess, rectal hemorrhage

GU: proteinuria, urinary frequency or urgency, nephrotic syndrome

Hematologic: leukopenia, neutropenia, hemorrhage

Hepatic: bilirubinemia

Metabolic: hypokalemia, hyponatremia

Musculoskeletal: myalgia, back pain

Respiratory: upper respiratory tract infection, dyspnea, massive hemoptysis

Skin: wound-healing complications, dry skin, exfoliative dermatitis, wound dehiscence

Other: abnormal taste, altered voice, pain, weight loss, infusion reaction


Drug-drug. Irinotecan: increased concentration of irinotecan metabolite

Drug-diagnostic tests. Leukocytes, potassium, sodium: decreased levels Urine protein: increased level

Patient monitoring

Monitor patient closely and discontinue drug if signs and symptoms of thromboembolism and GI perforation (such as abdominal pain, vomiting, and constipation), serious bleeding, nephrotic syndrome, or hypertensive crisis develops.

Stay alert for and discontinue drug if nongastrointestinal fistula formation, delayed wound healing, or wound dehiscence requiring medical intervention occurs.

Stay alert for and discontinue drug if signs and symptoms of leukoencephalopathy occur (such as headache, seizures, lethargy, confusion, or blindness).

• Assess blood pressure frequently.

• Monitor CBC with differential and urine protein and serum electrolyte levels.

Patient teaching

Tell patient to call prescriber immediately if he experiences dizziness, severe bleeding, stomach pain, or urinary problems or if a wound opens.

• Instruct patient to tell prescriber if he has been exposed to chickenpox or if he has gout, heart disease, viral infection, urinary problems, hepatic disease, or another form of cancer.

• Advise patient to tell prescriber if he has surgery planned; drug may delay wound healing.

• Caution patient not to get immunizations unless prescriber approves.

• Inform female patients of childbearing potential risk of ovarian failure before starting drug.

• Instruct female patient to tell prescriber if she is pregnant, plans to become pregnant, or is breast-feeding.

• As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs and tests mentioned above.

McGraw-Hill Nurse's Drug Handbook, 7th Ed. Copyright © 2013 by The McGraw-Hill Companies, Inc. All rights reserved


A trademark for the drug bevacizumab.
The American Heritage® Medical Dictionary Copyright © 2007, 2004 by Houghton Mifflin Company. Published by Houghton Mifflin Company. All rights reserved.


A humanised monoclonal antibody which inhibits vascular endothelial growth factor (VEGF) which has anti-angiogenic effects, and is used to treat colorectal, lung and kidney cancers, as well as glioblastomas. It is not FDA-approved for managing breast cancer.

Adverse effects
Hypertension, haemorrhage.
Segen's Medical Dictionary. © 2012 Farlex, Inc. All rights reserved.
References in periodicals archive ?
We are delighted that Avastin is now available to women across the country."
Milad Kamal Ayad, who works on commission for Egyptian firm SAWA, told Reuters he sourced 167 packets of Avastin from Turkey, via a Syrian businessman also based in Egypt, for Swiss-based Hadicon AG.
Margaret Hamburg said she is revoking the approval, because the use of Avastin as a first-line treatment for metastatic breast cancer has not been shown to be safe and effective.
The Florida Department of Health (DOH) notified FDA of a cluster of Streptococcus endophthalmitis infections in three clinics following intravitreal injection of repackaged Avastin.
Avastin (bevacizumab), the top-selling cancer drug in the world, is useful for some cancers, including lung, colon, kidney, and brain cancer.
They will continue to pay when for Avastin when prescribed, even for breast cancer treatment.
later, and Avastin wound up posting a 5% decline in 4Q10 and a 6% drop
Nice appraised Avastin in combination with a type of chemotherapy for treating breast cancer which has spread around the body.
Adding Avastin (bevacizumab) to chemotherapy can slow down progression of ovarian cancer, which kills more than 4,000 women a year in the UK.
Avastin (bevacizumab) can help patients with advanced bowel cancer which has spread to other organs.
Summary: TEHRAN (FNA)- Iranian nanotechnology researchers have recently found a drug delivery system with long-term delivery for Bevacizuamb (Avastin) which is used for the treatment of intraocular blood vessel damages.